The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System

Juan Guillermo Ariza; Per-Olof Thuresson; Gerardo Machnicki; Laura Mungapen; Matthias Kraemer; Yumi Asukai; Luis Fernando Giraldo

doi:10.1016/j.vhri.2012.09.003

The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System

Value Health Reg Issues. 2012 Dec;1(2):165-171. doi: 10.1016/j.vhri.2012.09.003. Epub 2012 Dec 12.

Authors

Juan Guillermo Ariza¹, Per-Olof Thuresson², Gerardo Machnicki³, Laura Mungapen⁴, Matthias Kraemer⁵, Yumi Asukai⁴, Luis Fernando Giraldo⁶

Affiliations

¹ Novartis, Bogotá, Colombia.
² IMS Health, Basel, Switzerland.
³ Novartis Latin America and Canada, Buenos Aires, Argentina. Electronic address: gerardo.machnicki@novartis.com.
⁴ IMS Health, London, UK.
⁵ Novartis Pharma AG, Basel, Switzerland.
⁶ Clinica Universitaria Teletón, Universidad de La Sabana, Chia, Colombia.

PMID: 29702896
DOI: 10.1016/j.vhri.2012.09.003

Abstract

Objectives: The main objectives were to estimate the cost-effectiveness and budget impact of indacaterol (a once-daily, long-acting-beta₂-agonist) compared with 1) salmeterol/fluticasone, 2) formoterol/budesonide, and 3) tiotropium for the treatment of chronic obstructive pulmonary disease in Colombia.

Methods: A Markov model was utilized to simulate the progressive course of chronic obstructive pulmonary disease, distinguished by forced expiratory volume in 1 second predicted according to the four Global Initiative for Chronic Obstructive Lung Disease severity stages by using prebronchodilation values. Efficacy was based on the initial improvement in forced expiratory volume in 1 second, taken from either a network meta-analysis (salmeterol/fluticasone and formoterol/budesonide) or a randomized controlled trial (tiotropium). Colombian direct costs and life tables were incorporated in the adaptation, and analysis was performed from a health care payer perspective, discounting future costs (presented as US dollars) and benefits at 5%. A budget impact model was built to estimate the cost impact of indacaterol in Colombia over 3 and 5 years.

Results: Indacaterol was found to be dominant (i.e., less costly and more effective) against both salmeterol/fluticasone and formoterol/budesonide per life year and quality-adjusted life-year gained after a 5-year time horizon. The average cost saving against salmeterol/fluticasone and formoterol/budesonide was US $411 and US $909 per patient, respectively. All probabilistic sensitivity analysis simulations indicated indacaterol to be less costly than salmeterol/fluticasone and formoterol/budesonide. Indacaterol was more effective and more costly than tiotropium, corresponding to an incremental cost-utility ratio of US $2584 per quality-adjusted life-year.

Conclusions: The results indicate that by replacing salmeterol/fluticasone or formoterol/budesonide with indacaterol, there are possible cost savings for the Colombian health care system. This was demonstrated by both cost-effectiveness and budget impact models.

Keywords: COPD; Colombia; cost-effectiveness; indacaterol.